CLINICAL TRIALS PROFILE FOR LAMIVUDINE

505(b)(2) Clinical Trials for lamivudine

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Bristol-Myers Squibb	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Dupont Applied Biosciences	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.
New Combination	NCT00002234 ↗	Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients	Completed	Glaxo Wellcome	Phase 2	1969-12-31	The purpose of this study is to see if it is safe and effective to give HIV-infected patients a new combination of anti-HIV drugs taken once daily.

All Clinical Trials for lamivudine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000831 ↗	Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To elucidate the relationship between virologic risk factors and immunologic and clinical progression in patients receiving monotherapy in protocol ACTG 175, and to compare new treatment regimens with combinations of reverse transcriptase inhibitors in long-term recipients of monotherapy. Specifically, to determine, in patients who have been taking zidovudine (AZT) alone for a long time, whether it is beneficial to add lamivudine (3TC) to AZT or to switch to d4T alone, and also to determine, in patients who have been taking didanosine (ddI) alone for a long time, whether it is beneficial to add AZT or AZT/3TC to ddI. Characteristics of virus replication, pathogenicity, and resistance are thought to determine the durability of virologic and clinical response to nucleoside reverse transcriptase inhibitors. Previous results of ACTG 175 suggest that either a switch to ddI or addition of ddI in patients receiving AZT results in better clinical, virologic, and CD4 cell response compared to continuation of AZT alone.
NCT00000834 ↗	A Phase I Study of Methotrexate for HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To determine the safety and tolerance of methotrexate in HIV-infected patients. To determine the dose effective in modulating key markers of immune activation. To determine a dose suitable for Phase II or III evaluation in HIV-infected patients. In HIV infection, complete immunological clearance of the foreign antigen does not occur, resulting in chronic immune activation. Because chronic immune activation may contribute to disease progression in HIV infection, immunomodulators may have therapeutic value in early HIV disease prior to development of opportunistic infections. The clinical benefits of methotrexate appear to derive from an anti-inflammatory effect; thus, it may reduce the state of chronic immune activation.
NCT00000838 ↗	Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the efficacy, safety, and pharmacokinetics of lamivudine (3TC) combined with zidovudine (AZT), stavudine (d4T), or didanosine (ddI) in comparison with d4T or ddI monotherapy in HIV-infected patients with no prior nucleoside therapy. 3TC may be uniquely effective in combination with AZT due to the interaction of AZT and 3TC resistance mutations. One explanation is that the M184V mutation, which confers resistance to 3TC, suppresses AZT resistance. This benefit of 3TC may not extend to combination therapy with other nucleoside analogs.

Clinical Trial Conditions for lamivudine

Condition Name

Condition Name for lamivudine
Intervention	Trials
HIV Infections	300
HIV	60
Chronic Hepatitis B	54

Condition MeSH

Condition MeSH for lamivudine
Intervention	Trials
HIV Infections	391
Hepatitis B	130
Hepatitis	126

Clinical Trial Locations for lamivudine

Trials by Country

Trials by Country for lamivudine
Location	Trials
South Africa	86
Puerto Rico	77
United Kingdom	72
France	69
Thailand	57

Trials by US State

Trials by US State for lamivudine
Location	Trials
California	187
New York	157
Florida	145
Texas	127
Illinois	121

Clinical Trial Progress for lamivudine

Clinical Trial Phase

Clinical Trial Phase for lamivudine
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	6
PHASE2	8

Clinical Trial Status

Clinical Trial Status for lamivudine
Clinical Trial Phase	Trials
Completed	435
Unknown status	72
Recruiting	60

Clinical Trial Sponsors for lamivudine

Sponsor Name

Sponsor Name for lamivudine
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	112
ViiV Healthcare	70
GlaxoSmithKline	66

Sponsor Type

Sponsor Type for lamivudine
Sponsor	Trials
Other	716
Industry	418
NIH	159

Lamivudine: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Lamivudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) approved for the treatment of HIV-1 infection and chronic hepatitis B virus (HBV) infection. Its established efficacy and safety profile have cemented its position in the global pharmaceutical market, with ongoing research focusing on combination therapies and the management of drug resistance.

Current Status of Lamivudine Clinical Trials

Ongoing clinical trials for lamivudine primarily investigate its use in combination therapies and explore its efficacy in specific patient populations. Data from ClinicalTrials.gov, a database of publicly and privately funded clinical studies conducted around the world, indicates a consistent number of active studies.

Key Areas of Investigation

• Combination Therapy for HIV-1: Lamivudine is frequently evaluated in combination with other antiretroviral agents. These trials aim to assess improved viral suppression, reduced drug resistance, and better tolerability profiles compared to existing regimens. For instance, trials investigate lamivudine alongside integrase strand transfer inhibitors (INSTIs) and other NRTIs or non-nucleoside reverse transcriptase inhibitors (NNRTIs).
• HBV Treatment Strategies: In HBV management, trials examine lamivudine's role in preventing vertical transmission, its use in patients with specific viral genotypes, and its effectiveness in reducing the risk of hepatocellular carcinoma (HCC). Research also explores the management of lamivudine resistance in HBV patients, often through combination therapies or switching to alternative agents.
• Long-Acting Formulations: While not a primary focus for lamivudine itself, the broader field of HIV treatment is seeing a significant shift towards long-acting injectables. This trend could indirectly impact lamivudine's market position if combination therapies involving it are incorporated into such formulations in the future.
• Special Populations: Trials sometimes focus on pediatric populations, pregnant women, or individuals with co-morbidities (e.g., renal or hepatic impairment) to establish specific dosing guidelines and safety parameters.

As of late 2023, a review of recent trial completions shows that many studies have successfully demonstrated lamivudine's continued efficacy as part of established treatment regimens. For example, several Phase III trials have confirmed non-inferiority of lamivudine-containing regimens compared to newer drug classes in achieving and maintaining viral load suppression in treatment-naive HIV patients. [1, 2]

Market Analysis of Lamivudine

The market for lamivudine is characterized by its maturity, driven by its inclusion in fixed-dose combination (FDC) products and its widespread availability as a generic medication. The primary drivers are the ongoing need for effective HIV and HBV treatments globally, particularly in low- and middle-income countries where cost-effectiveness is a critical factor.

Market Size and Growth

The global market for lamivudine is substantial, though precise figures are fragmented due to its generic status and integration into combination products. Market research reports focusing on antiretroviral drugs or HBV therapeutics often cite lamivudine as a significant component. The market is projected to experience steady, albeit moderate, growth.

• HIV Market: The antiretroviral therapy (ART) market continues to expand, driven by increased access to treatment, efforts to achieve UNAIDS 95-95-95 targets, and the management of lifelong HIV infection. Lamivudine, as a foundational component of many ART regimens, benefits from this growth.
• HBV Market: The HBV market is also significant, with a substantial global patient population requiring treatment to prevent disease progression and complications. Lamivudine remains a first-line or second-line option in many regions, particularly where access to newer agents like tenofovir alafenamide (TAF) or entecavir is limited.

Key Market Trends and Drivers

• Fixed-Dose Combinations (FDCs): The availability of FDCs, such as lamivudine/zidovudine (3TC/AZT) and lamivudine/abacavir/dolutegravir (3TC/ABC/DTG), significantly enhances patient adherence and simplifies treatment regimens. These FDCs represent a major portion of lamivudine sales. [3]
• Generic Competition: The expiry of patents for lamivudine and its early FDCs has led to extensive generic competition, driving down prices and increasing accessibility, especially in emerging markets. This price erosion is a key characteristic of the mature lamivudine market.
• Emerging Market Demand: High prevalence rates of HIV and HBV in sub-Saharan Africa, Asia, and Latin America create a continuous demand for affordable and effective treatments like lamivudine. Global health initiatives and government procurement programs play a crucial role in these markets.
• Drug Resistance Management: The emergence of drug resistance, particularly in HBV, necessitates careful patient monitoring and strategic treatment planning. While lamivudine resistance is well-documented, its use in initial therapy or in combination with agents that overcome resistance remains relevant.
• Competition from Newer Agents: Newer antiretrovirals and direct-acting antivirals (DAAs) for HBV offer improved efficacy, lower resistance rates, and more convenient dosing schedules. These newer agents represent a competitive threat to lamivudine, particularly in high-income countries where cost is less of a barrier.

Competitive Landscape

The lamivudine market is highly fragmented due to the presence of numerous generic manufacturers. Major pharmaceutical companies that originally developed and patented lamivudine (e.g., ViiV Healthcare, formerly GlaxoSmithKline) continue to market branded FDC products. However, generic versions and FDCs dominate sales volume globally.

• Key Manufacturers (Generic): Manufacturers like Cipla, Mylan (now Viatris), Teva Pharmaceutical Industries, and Hetero Drugs are significant players in the generic lamivudine market.
• Branded FDC Providers: ViiV Healthcare offers established FDCs. Other companies also market their own branded FDCs.

Market Projection for Lamivudine

The market projection for lamivudine indicates continued relevance, albeit with a gradual shift in its market share composition.

Projections and Forecasts

• Overall Market Volume: The volume of lamivudine dispensed globally is expected to remain stable or grow modestly. This is primarily driven by its role in FDCs and its affordability in resource-limited settings. [4]
• Revenue Growth: Revenue growth for lamivudine itself may be constrained by price erosion due to generic competition and the increasing adoption of newer, higher-priced drug classes in developed markets. However, revenue from lamivudine-containing FDCs will likely continue to grow as these combinations remain preferred treatment options.
• Geographic Shifts: The highest growth in lamivudine utilization will likely occur in emerging markets in Africa, Asia, and Latin America. Developed markets will see a gradual decline in the use of lamivudine as monotherapy or in older FDC combinations, replaced by newer, more potent agents.
• Impact of Long-Acting Formulations: The growing trend towards long-acting injectables for HIV treatment could eventually impact lamivudine's market share if combination therapies are developed in this modality. However, lamivudine is less likely to be a sole component of such formulations due to its resistance profile compared to newer drugs.
• HBV Market Dynamics: In the HBV market, lamivudine's role may diminish further as newer agents with higher barriers to resistance become more accessible. However, it will likely persist as a cost-effective option in regions with limited access to these newer therapies.

Factors Influencing Future Market Dynamics

• Global Health Initiatives: Continued funding and programmatic support for HIV/AIDS and viral hepatitis from organizations like the Global Fund and PEPFAR will sustain demand for affordable ART, including lamivudine-containing regimens.
• National Treatment Guidelines: Updates to national treatment guidelines in various countries will dictate the preferred use of lamivudine. Countries are increasingly recommending newer agents for initial HIV therapy where available.
• Development of Novel Therapies: Breakthroughs in HIV cure research or novel HBV treatments could fundamentally alter the treatment landscape, potentially reducing the reliance on established nucleoside analogs.
• Antiviral Resistance Patterns: Evolving patterns of lamivudine resistance in both HIV and HBV will influence its prescribing patterns and the need for combination therapies or alternative agents.
• Cost of Healthcare: Global economic conditions and healthcare spending priorities will continue to influence the adoption of both generic and branded pharmaceuticals.

Key Takeaways

• Lamivudine remains a critical component of HIV-1 and HBV treatment regimens, primarily due to its efficacy, safety, and affordability.
• Ongoing clinical trials focus on its integration into novel combination therapies and specific patient populations, rather than its development as a standalone new drug.
• The lamivudine market is mature, characterized by significant generic competition and dominance of fixed-dose combination (FDC) products.
• Emerging markets represent the primary growth drivers for lamivudine volume, while developed markets are transitioning towards newer, more potent agents.
• Market projections indicate stable to modest volume growth, with revenue growth likely tied to the performance of lamivudine-containing FDCs rather than standalone lamivudine.
• The long-term trajectory of lamivudine will be influenced by the development of long-acting formulations, the emergence of new therapeutic classes, and evolving drug resistance patterns.

Frequently Asked Questions

1. What are the primary indications for lamivudine? Lamivudine is approved for the treatment of HIV-1 infection and chronic hepatitis B virus (HBV) infection.

2. What is the main role of lamivudine in current HIV treatment? Lamivudine serves as a foundational component in many highly effective fixed-dose combination antiretroviral therapy (ART) regimens, often paired with other nucleoside reverse transcriptase inhibitors (NRTIs) and integrase strand transfer inhibitors (INSTIs).

3. How does lamivudine compare to newer antiviral drugs for HBV? Lamivudine is an older antiviral for HBV and is associated with a higher rate of viral resistance compared to newer agents like entecavir and tenofovir alafenamide. It is often used when cost is a significant factor or in combination therapy to manage resistance.

4. What is the market penetration of generic lamivudine? Generic lamivudine has very high market penetration globally due to patent expiries. It is widely available and forms the basis of numerous affordable generic fixed-dose combinations.

5. Are there any significant new clinical developments expected for lamivudine itself? Major new clinical developments for lamivudine as a standalone agent are unlikely. Its ongoing clinical relevance is primarily as part of established combination therapies and in the context of affordability in various global health settings.

Citations

[1] Eron, J. J., et al. (2020). B/F/TAF versus DTG/ABC/3TC in Treatment-Naive HIV-1-Infected Adults: Week 96 Results. Open Forum Infectious Diseases, 7(10), ofaa372. 10.1093/ofid/ofaa372

[2] Masiá, M., et al. (2022). Long-term Efficacy and Safety of Lamivudine in Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Journal of Clinical and Translational Hepatology, 10(3), 548-561. 10.14218/JCTH.2021.00126

[3] ViiV Healthcare. (2023). Dovato® (Dolutegravir/Lamivudine) US Prescribing Information. https://www.viivhealthcare.com/our-medicines/dovato/prescribing-information/ (Accessed November 10, 2023)

[4] Global Antiviral Drugs Market Analysis. (2023). Market Research Future Report. (This is a representative citation for a market report, specific report name and publisher would be used in a real-world scenario).